A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma

Inclusion Criteria: * Patients aged 19 to 70 * Patients diagnosed with newly diagnosed glioblastoma based on medical imaging after receiving standard therapy for glioblastoma * Patients whose expected survival period is at least 3 months * Patients who have not received any other types of immunotherapy * Patients who have been given a sufficient explanation of the purpose and details of the clinical trial and the characteristics of the investigational drug from an investigator and who signed the consent form or had a legal guardian or representative sign the consent form prior to the beginning of this clinical trial Exclusion Criteria: * Patients with recurrent glioblastoma. Known Dihydropyrimidine Dehydrogenase (DPD) deficiency Contraindications to contrast-enhanced MRI (e.g., patients with pacemakers or other reasons preventing MRI scans according to the study schedule) * Patients who received Gliadel wafer implantation during surgery * Patients with severe dysfunction of major organs (liver, kidney, bone marrow, lung, heart) as determined by the investigator * Patients with concurrent malignancies other than glioblastoma or a history of malignancy within the past 5 years * Patients with uncontrolled hypotension or hypertension * Patients with serious infections as determined by the investigator, including sepsis, hepatitis A, B, or C * Patients with a Karnofsky Performance Scale (KPS) score \< 50 * Patients with autoimmune diseases involving the central nervous system (e.g., multiple sclerosis, myasthenia gravis, acute disseminated encephalomyelitis) * Patients with a history of allergy to flucytosine (5-FC), its excipients, or 5-fluorouracil (5-FU) * Pregnant or breastfeeding women, patients planning to become pregnant during the study period, or those unwilling to use appropriate contraception * Participation in another clinical trial within 30 days prior to enrollment * Any condition that, in the opinion of the investigator, would make the patient unsuitable for study participation